3B BlackBio Dx Posts FY26 Revenue of ₹142 Cr, Profit ₹60 Cr

Consolidated Revenue (FY26): ₹142 crore
Consolidated PAT (FY26): ₹60 crore

Reader Takeaway: Growth driven by acquisitions and international markets; focus on high-margin niches. US FDA approval timeline uncertain.

What just happened

3B BlackBio Dx Ltd announced its consolidated financial results for the fiscal year ended March 2026. The company reported a revenue of ₹142 crore and a profit after tax (PAT) of ₹60 crore. This performance was bolstered by contributions from its international operations and its Indian diagnostic business.

Why this matters

The reported figures indicate a period of growth for the company, with the PAT significantly benefiting from international segments. Management's guidance for FY27, targeting 15% to 20% revenue growth, provides investors with an outlook for the upcoming fiscal year. The company's strategic focus on high-margin specialized diagnostic panels aims to mitigate risks associated with price erosion in high-volume markets.

The backstory

For FY26, the 3B India Molecular Diagnostic segment reported ₹86.47 crore in revenue, a normalization after a strong FY25. TRUPCR Europe showed sustained growth with ₹20.67 crore in revenue. The recent acquisition of Coris BioConcept contributed ₹35.91 crore in revenue over seven months post-acquisition.

Total depreciation increased to ₹5.12 crore in FY26 from ₹1.08 crore in FY25, mainly due to the amortization of capitalized R&D expenses for Coris BioConcept in line with Belgian accounting norms.

What changes now

The company is actively pursuing US FDA approval for its 'Resist-5' and 'Carba5' AMR products, seeing this as a significant market opportunity. Compliance with European IVDR regulations is also a priority, with BSI appointed as the notified body and QMS audits completed. Management has also stated that earnings conference calls will shift to a half-yearly frequency from next year.

Risks to watch

Key watch points include the uncertain timeline for US FDA approval, which directly impacts potential revenue from new product launches. The integration of Coris BioConcept may see short-term margin impacts due to seasonal losses, although the focus remains on full-year performance. The company must also actively manage competition from smaller players in low-priced assay markets.

Peer comparison

Information on specific peers and their comparable financial data for FY26 is not detailed in the filing. However, the company's strategy to focus on specialized, high-margin diagnostics contrasts with companies operating primarily in high-volume, single-test markets.

Context metrics (time-bound)

Consolidated Revenue FY26: ₹142 crore
Consolidated PAT FY26: ₹60 crore
EBITDA margins expected to remain stable in FY27.
Cash reserves stand at ₹50 crore.

What to track next

Investors will be looking for updates on US FDA approval progress and the successful integration of Coris BioConcept. Monitoring the performance of international operations and adherence to the FY27 revenue growth guidance of 15-20% will be crucial.